Melatonin API Manufacturers & Suppliers

Melatonin is used to manage circadian rhythm sleep disorders, including jet lag, insomnia, shift‑work disorder, and sleep‑wake disturbances in blind individuals. It is also used in pediatric patients with neurodevelopmental conditions who experience prolonged sleep‑onset latency. Its effects arise from MT1 and MT2 receptor–mediated regulation of the sleep–wake cycle.

Melatonin belongs to the following therapeutic categories: Amines, Antioxidants, Biogenic Amines, Biogenic Monoamines, Biological Factors. This positioning helps teams compare alternative APIs, anticipate pharmacology expectations, and align early research priorities.

The primary indications for Melatonin: Used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal, Evidence indicates that Melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults, It has received FDA orphan drug status as an oral medication for this use, A number of studies have shown that Melatonin may be effective for treating sleep-wake cycle disturbances in children and adolescents with mental retardation, autism, and other central nervous system disorders. These use cases frame the target patient populations and help prioritize formulation and safety evaluations.

Melatonin is a derivative of tryptophan. It binds to Melatonin receptor type 1A, which then acts on adenylate cylcase and the inhibition of a cAMP signal transduction pathway. Melatonin not only inhibits adenylate cyclase, but it also activates phosphilpase C. This potentiates the release of arachidonate. By binding to Melatonin receptors 1 and 2, the downstream signallling cascades have various effects in the body. The Melatonin receptors are G protein-coupled receptors and are expressed in various tissues of the body. There are two subtypes of the receptor in humans, Melatonin receptor 1 (MT1) and Melatonin receptor 2 (MT2). Melatonin and Melatonin receptor agonists, on market or in clinical trials, all bind to and activate both receptor types.The binding of the agonists to the receptors has been investigated for over two decades or since 1986. It is somewhat known, but still not fully understood. When Melatonin receptor agonists bind to and activate their receptors it causes numerous physiological processes. MT1 receptors are expressed in many regions of the central nervous system (CNS): suprachiasmatic nucleus of the hypothalamus (SNC), hippocampus, substantia nigra, cerebellum, central dopaminergic pathways, ventral tegmental area and nucleus accumbens. MT1 is also expressed in the retina, ovary, testis, mammary gland, coronary circulation and aorta, gallbladder, liver, kidney, skin and the immune system. MT2 receptors are expressed mainly in the CNS, also in the lung, cardiac, coronary and aortic tissue, myometrium and granulosa cells, immune cells, duodenum and adipocytes. The binding of Melatonin to Melatonin receptors activates a few signaling pathways. MT1 receptor activation inhibits the adenylyl cyclase and its inhibition causes a rippling effect of non activation; starting with decreasing formation of cyclic adenosine monophosphate (cAMP), and then progressing to less protein kinase A (PKA) activity, which in turn hinders the phosphorilation of cAMP responsive element-binding protein (CREB binding protein) into P-CREB. MT1 receptors also activate phospholipase C (PLC), affect ion channels and regulate ion flux inside the cell. The binding of Melatonin to MT2 receptors inhibits adenylyl cyclase which decreases the formation of cAMP.As well it hinders guanylyl cyclase and therefore the forming of cyclic guanosine monophosphate (cGMP). Binding to MT2 receptors probably affects PLC which increases protein kinase C (PKC) activity. Activation of the receptor can lead to ion flux inside the cell.

Melatonin has a generally favorable safety profile, with adverse effects that are typically mild and include daytime drowsiness, headache, dizziness, transient mood changes, tremor, gastrointestinal discomfort, reduced alertness, and hypotension. Developmental effects have been noted, including potential suppression of gonadal maturation in individuals with high endogenous Melatonin production and ovulation inhibition at high exposures in animal and clinical settings. It can interact with CNS depressants and with CYP1A2 inhibitors due to its metabolic pathway. Long‑term toxicity data are limited.

Melatonin’s low aqueous solubility often requires solubilizers, dispersion techniques, or suitable excipients to achieve uniform dosing, especially in liquid or extended‑release formats. Its light sensitivity necessitates protection from UV exposure during manufacturing and storage. Oral and sublingual forms are common, and food‑dependent absorption should be considered when designing release profiles.

Melatonin is classified as a small molecule. That classification shapes process design, impurity profiling, and analytical control strategies.

Oral Melatonin is chemically stable but sensitive to light, so exposure to UV should be minimized during manufacturing and storage. Its low aqueous solubility can affect physical stability in liquid or extended‑release formulations, sometimes requiring solubilizers or solid‑dispersion approaches. No additional stability concerns are noted beyond these formulation and handling considerations.